局部晚期非小细胞肺癌同步整合加量调强放疗与常规调强放疗的疗效与安全性比较:回顾性研究
该回顾性研究纳入426例III期非小细胞肺癌患者,比较同步整合加量调强放疗(SIB-IMRT)与常规IMRT的疗效与安全性。SIB-IMRT组IIIB期比例更高、计划靶区体积更大,但两组中位总生存(34.5 vs 31.7个月)、无进展生存、局部区域无失败生存及远处转移无失败生存均无差异,肺与食管毒性相似。SIB-IMRT可能是局部晚期NSCLC有效且安全的选择。
要点
- SIB-IMRT组IIIB期比例更高(69.5% vs 53%,P=0.002),计划靶区体积更大(中位504ml vs 402ml,P<0.001)。
- 两组中位总生存分别为34.5和31.7个月,2年总生存率分别为60.4%和59%(P=0.797)。
- 两组无进展生存、局部区域无失败生存、远处转移无失败生存及肺食管毒性均无差异。
核心结论
- SIB-IMRT可能是局部晚期非小细胞肺癌有效且安全的选择,尤其适用于大肿块或广泛淋巴结转移患者。
研究设计与样本
- 回顾性分析2014至2016年接受胸部IMRT的组织学确诊III期NSCLC患者,共426例,其中SIB-IMRT组128例、常规IMRT组298例。
主要发现
- SIB-IMRT组IIIB期比例更高(69.5% vs 53%,P=0.002),计划靶区体积更大(中位504ml vs 402ml,P<0.001),计划靶区体积与肺体积比更高(中位0.18 vs 0.12,P<0.001)。
- SIB-IMRT组与常规IMRT组中位总生存分别为34.5和31.7个月,2年总生存率分别为60.4%和59%(P=0.797)。
- 两组无进展生存、局部区域无失败生存及远处转移无失败生存均无差异,肺与食管毒性相似。
关键数值与推荐
- SIB-IMRT计划:PTV处方剂量45-59.4Gy(中位50.4Gy),同时PGTV处方剂量50-70Gy(中位59.92Gy)。
- 常规IMRT计划:PTV总剂量50-70Gy(中位60Gy)。
临床怎么用
- 对于局部晚期NSCLC,尤其大肿块或广泛淋巴结转移者,可考虑SIB-IMRT,但需注意该结论来自回顾性研究。
局限性
- 本研究为回顾性分析,两组基线特征(如分期、靶区体积)存在差异,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Consistent results are lacking as regards the comparative effectiveness of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) versus conventional intensity-modulated radiotherapy in patients with locally advanced non-small-cell lung cancer (LA-NSCLC). Therefore, we conducted a retrospective analysis to demonstrate the role of SIB-IMRT for patients. METHODS: Patients who had histologically confirmed NSCLC, stage III disease and received thoracic IMRT between 2014 and 2016 were retrospectively reviewed. The survival, toxicities and dose to organs at risk (OAR) were compared among patients irradiated with different techniques. The SIB-IMRT plans were designed to deliver 45-59.4Gy (median: 50.4Gy) to PTV while simultaneously delivering 50-70Gy (median: 59.92Gy) to PGTV. As for conventional IMRT plans, a total dose of 50-70Gy (median: 60Gy) was delivered to PTV. RESULTS: 426 patients with stage III NSCLC were eligible for analysis, including 128 with SIB-IMRT and 298 with conventional IMRT. The SIB-IMRT group had more stage IIIB disease (69.5% vs. 53%, P = 0.002), larger planning treatment volumes (median: 504 ml vs. 402 ml, P<0.001), and a larger planning treatment volume/volume of lung ratio (median, 0.18 vs. 0.12, P<0.001). The median OS of the SIB-IMRT and conventional IMRT groups were 34.5 and 31.7 months, with the 2-year rate of 60.4 and 59%, respectively (P = 0.797). No difference in PFS, LRFS or DMFS was observed between the two techniques. Patients treated with SIB-IMRT got similar lung and esophageal toxicities versus those with conventional IMRT. CONCLUSIONS: SIB-IMRT may be an effective and safe option for patients with locally advanced NSCLC, especially for those with large mass or wide lymph node metastasis.
引用
- Wang D, Bi N, Zhang T, et al. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. Radiat Oncol. 2019. PMID: 31196118. doi:10.1186/s13014-019-1259-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。